 Want to learn about stocks, cryptocurrencies, NFTs, and the metaverse? Join RichTV.io. Hey guys, how are you doing? This is your boy Rich from RichTV Live. We got big breaking news from Solagenics, SNGX on the NASDAQ. Solagenics, put on your radar, put on your watch list, big breaking news, announced submission of new drug application to the FDA for a hybride in the treatment of cutaneous T-cell lymphoma. Huge breaking news exclusively here on RichTV Live. We're gonna break down the news. We're gonna look at the chart. We're gonna break down the opportunity right here, right now. Solagenics announces submission of new drug application to the FDA for a hybride in the treatment of cutaneous T-cell lymphoma. Huge, huge breaking news exclusively here on RichTV Live from Solagenics, Inc. On the NASDAQ listed under the symbol SNGX. This is what it looks like here. This is the chart and we're gonna break down the news. I just wanna kinda show you on chart where it looks. You can see currently sitting at 54 cents. It's got a high, I'm just under a dollar and a low in the last year of 38 cents and currently sitting right at 54 at the bottom of the Fibonacci. So lots of room for this to go higher and lots of room for this to extend to those higher zones and get back to those higher levels. So great opportunity as far as I'm concerned for investors at these levels. Now let's get into the news. Big breaking news. Solagenics or the company, a late stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need announced today that is submitted a new drug application, NDA to the United States, US Food and Drug Administration, FDA for Hybride, which is trademarked. And you can see here some of the things they specialize right on their website at solagenics.com. Now this is for synthetic hyporocene in the treatment of early stage cutaneous T-cell lymphoma otherwise known as CTCL, a rare cancer an area of unmet medical need affecting over 25,000 patients in the United States. The company estimates the potential worldwide market for Hybride to be in access of 250 million for the treatment of CTCL. So this is huge breaking news and you can find all the information you're looking for right on the company website at solagenics.com. The submission of our NDA is significant milestone for Solagenics positioning us well to fulfill our promise to offer an innovative first in-class therapy to the CTCL community of patients, families and healthcare professionals stated Christopher J. Shaver PhD president and chief executive officer of Solagenics. CTCL is an incredibly difficult to treat orphan disease and remains an area of unmet medical need with a very limited number of safe and effective treatment options. So you can learn more about this and everything we're talking about right on the company website. You can see featured videos and I'm also gonna show you a little bit of information here on the website. You can find their corporate presentation, latest news and resources right here on their website. You wanna look at pipeline and programs, click on pipeline and programs about Solagenics, click on about Solagenics and you can learn everything about the company right on their website. Now further into the news, the clinical results we've generated throughout the development program support the potential for hybrid to serve as an important frontline treatment in the management of this chronic cancer. So a huge, huge focus and area of concern and obviously almost everybody has been touched by cancer and this is a company that's really focusing on solving some huge, huge needs. We look forward to working with the FDA through the review process as the NDA has been granted both FDA orphan drug and fast track designations. We anticipate potential approval in the second half of 2023 as we continue advancing our preparations for US launch which is currently targeted for the first quarter 2024 about cutaneous T cell lymphoma CTCL. So this is obviously a topic of focus. This is huge breaking news and of course we're bringing it to you first. You can learn more about Solagenics right here on their social media. This is their Instagram. This is their Twitter. All of this is found right on their website at the bottom of the page. This is their Facebook and their YouTube. I'd love to get to know companies by following everything they do. You can see their areas of focus here and you can see their partners. And here it is, cutaneous T cell lymphoma. So a little bit more about it. CTCL is a class of non-hardskins lymphoma NHL, a type of cancer of the white blood cells that are an integral part of the immune system. Unlike most NHLs which generally involve B cell lymphocytes involved in producing antibodies, CTCL is caused by an expansion of malignant T cell lymphoma sites. Normally programmed to mitigate to the skin. These malignant cells migrate to the skin where they form various lesions, typically beginning as patches and may progress to raised tumors. Mortality is related to the stage of CTCL with median survival generally ranging from about 12 years in the early stages to only 2.5 years when the disease has advanced. There's currently no cure for CTCL. Typically CTCL lesions are treated and regressed but usually return either in the same part of the body or in new areas. CTCL constitutes a rare group of NHLs occurring in about 4% of the approximately 700,000 individuals living with the disease. It is estimated based upon review of historic published studies and reports and interpolation of data on the incidence of CTCL that affects over 25,000 individuals in the United States with approximately 3,000 new cases seen annually. So this is a major need and this is what Solagenix is focused on as a major focus right now. And you can see here more information on the website. You can continue to just scroll down and learn all of this information right at Solagenix.com and feel free to learn more there. You can see who they're partnering with and there's an investor section as well for investors within our community that wanna learn more about the company. You wanna learn about their stock data, feature presentations, some quick links right here under investors. Now a little bit about Solagenix. Solagenix is a late stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Their specialized biotherapeutics business segment is developing and moving towards commercialization of hybrid SGX-301 or synthetic hyperacine. A novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T cell lymphoma otherwise known as CTCL. You wanna learn more about the company you can see right here right on their website everything you need to know right at your fingertips. And this is how you can learn about companies. Feel free to contact the company. You can see all their information there and all their socials right at the bottom of the page right on their website. Thank you guys for watching. If you're not winning, you're probably not watching. We'd love to bring you the news. We'd love to bring you the analysis and we'd love to bring it to you first. What do you think of this news? What do you think of Solagenics Inc. With this huge news, a huge gap to fill here in the stock seems like everything is falling into place and this is just getting out there. This news is just getting out there. It's just starting to circulate. What do you think of this news? Remember Rich TV Live is strictly for information and education purposes. Please do your due diligence, do your research before you invest in anything we talk about or discuss. This is your host with the most, your boy Rich from Rich TV and I'm out.